Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy--Long-Term Outcome of a Phase II Pilot Study.

Wagner A, Wiedmann M, Tannapfel A, Mayr C, Kiesslich T, Wolkersdörfer GW, Berr F, Hauss J, Witzigmann H.

Int J Mol Sci. 2015 Nov 6;16(11):26619-28. doi: 10.3390/ijms161125978.

2.

New and emerging combination therapies for esophageal cancer.

Wiedmann MW, Mössner J.

Cancer Manag Res. 2013 Jun 27;5:133-46. doi: 10.2147/CMAR.S32199. Print 2013.

3.

Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors.

Wiedmann MW, Mössner J.

Clin Med Insights Oncol. 2012;6:381-93. doi: 10.4137/CMO.S7350. Epub 2012 Nov 20.

4.

Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.

Thrum S, Lorenz J, Mössner J, Wiedmann M.

Anticancer Res. 2011 Oct;31(10):3289-99.

PMID:
21965739
5.

Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study.

Roth A, Schleyer E, Schoppmeyer K, Kluge R, Wittekind C, Mössner J, Wiedmann M.

Onkologie. 2011;34(8-9):469-70. doi: 10.1159/000331065. Epub 2011 Aug 22. No abstract available.

PMID:
21934349
6.

Molecular targeted therapy of gastrointestinal cancer.

Wiedmann MW.

Curr Cancer Drug Targets. 2011 Jul;11(6):670-80. No abstract available.

PMID:
21787296
7.

Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies.

Wiedmann MW, Mössner J.

Curr Cancer Drug Targets. 2011 Jul;11(6):714-33.

PMID:
21599629
8.

Molecular targeted therapy of biliary tract cancer--results of the first clinical studies.

Wiedmann MW, Mössner J.

Curr Drug Targets. 2010 Jul;11(7):834-50. Review.

PMID:
20388063
9.

Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.

Wolf S, Lorenz J, Mössner J, Wiedmann M.

World J Gastroenterol. 2010 Jan 14;16(2):156-66.

10.

Sudden elevation of liver enzymes in a 64-year-old patient: a case report.

Wiedmann M, Müller C, Lobeck H, Wölke K.

Cases J. 2009 Nov 18;2:205. doi: 10.1186/1757-1626-2-205.

11.

TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.

Wiedmann MW, Mössner J, Baerwald C, Pierer M.

Endocr Metab Immune Disord Drug Targets. 2009 Sep;9(3):295-314. Epub 2009 Sep 1. Review.

PMID:
19594416
12.

Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.

Haefner M, Bluethner T, Niederhagen M, Moebius C, Wittekind C, Mossner J, Caca K, Wiedmann M.

World J Gastroenterol. 2008 Jun 21;14(23):3681-92.

13.

Prognostic value of eicosanoid pathways in extrahepatic cholangiocarcinoma.

Möbius C, Aust G, Wiedmann M, Wittekind C, Mössner J, Hauss J, Witzigmann H.

Anticancer Res. 2008 Mar-Apr;28(2A):873-8.

14.

Therapeutical concepts and results for Klatskin tumors.

Witzigmann H, Wiedmann M, Wittekind C, Mössner J, Hauss J.

Dtsch Arztebl Int. 2008 Feb;105(9):156-61. doi: 10.3238/arztebl.2008.0156. Epub 2008 Feb 29.

15.

A pilot study of bendamustine in advanced bile duct cancer.

Schoppmeyer K, Kreth F, Wiedmann M, Mössner J, Preiss R, Caca K.

Anticancer Drugs. 2007 Jul;18(6):697-702.

PMID:
17762399
16.

Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.

Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M.

World J Gastroenterol. 2007 Sep 21;13(35):4761-70.

17.

Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial.

Feisthammel J, Schoppmeyer K, Mössner J, Schulze M, Caca K, Wiedmann M.

Am J Clin Oncol. 2007 Jun;30(3):319-24.

PMID:
17551313
18.

Wireless capsule endoscopy for diagnosis of acute intestinal graft-versus-host disease.

Neumann S, Schoppmeyer K, Lange T, Wiedmann M, Golsong J, Tannapfel A, Mossner J, Niederwieser D, Caca K.

Gastrointest Endosc. 2007 Mar;65(3):403-9.

PMID:
17321239
19.

Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial.

Schoppmeyer K, Miethe S, Wiedmann M, Liebmann A, Hauss J, Mossner J, Caca K, Witzigmann H, Hildebrandt G.

Am J Clin Oncol. 2006 Dec;29(6):576-82.

PMID:
17148994
20.

Management and outcome in patients with Klatskin-mimicking lesions of the biliary tree.

Uhlmann D, Wiedmann M, Schmidt F, Kluge R, Tannapfel A, Berr F, Hauss J, Witzigmann H.

J Gastrointest Surg. 2006 Sep-Oct;10(8):1144-50.

PMID:
16966034

Supplemental Content

Loading ...
Support Center